AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Harmony Biosciences Holdings: Buy Rating Maintained Despite Q2 Earnings Miss
ByAinvest
Wednesday, Aug 6, 2025 8:39 pm ET1min read
Harmony Biosciences Holdings has reported slightly lower-than-expected Q2 sales and EPS, but showed positive signs with an increase in Wakix therapy patients. The management reaffirmed full-year revenue guidance, and the pipeline remains on track with significant milestones expected. These developments support a Buy rating with a $49.00 price target. Mizuho Securities also maintains a Buy rating with a $48.00 price target.
Harmony Biosciences Holdings, Inc. (HRMY) recently reported its second-quarter 2025 financial results, showcasing a mixed performance with slightly lower-than-expected sales and earnings per share (EPS). The company reported an EPS of $0.92, beating the forecasted $0.72 by 27.78%, but its revenue of $200.5 million fell short of expectations at $204.59 million, representing a 16% year-over-year growth [2].Despite the revenue miss, the company demonstrated strong profitability metrics, with a 25% return on equity and 21% return on invested capital. The stock experienced a pre-market decline of 3.88%, trading at $34.16, reflecting investor caution despite the EPS beat [2].
Management reaffirmed its full-year revenue guidance, projecting between $820 million and $860 million. The company anticipates several key catalysts, including the release of ZYN-two Phase III data for Fragile X syndrome and the initiation of Pitolacin HD Phase III trials. The company’s strategic focus remains on expanding its pipeline and achieving potential peak sales of $3-6 billion [2].
Harmony Biosciences continues to capitalize on its lead product, Wakix, which saw a 400-patient increase, indicating sustained demand in the narcolepsy market. The company's strong cash position, with $672 million in cash and equivalents, supports its growth trajectory and potential for further expansion [2].
Mizuho Securities maintains a Buy rating with a $48.00 price target, while Zacks Investment Research also maintains a Buy rating with a $49.00 price target, supporting the stock's potential for growth [1].
References:
[1] https://www.nasdaq.com/articles/harmony-biosciences-holdings-inc-hrmy-misses-q2-earnings-and-revenue-estimates
[2] https://www.investing.com/news/transcripts/earnings-call-transcript-harmony-biosciences-q2-2025-beats-eps-expectations-93CH-4170933
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet